nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—RRM1—lung cancer	0.22	0.797	CbGaD
Cladribine—Azacitidine—Gemcitabine—lung cancer	0.0849	0.512	CrCrCtD
Cladribine—Decitabine—Gemcitabine—lung cancer	0.0809	0.488	CrCrCtD
Cladribine—ABCG2—lung cancer	0.0561	0.203	CbGaD
Cladribine—POLE—Gemcitabine—lung cancer	0.056	0.152	CbGbCtD
Cladribine—DCK—Pemetrexed—lung cancer	0.055	0.149	CbGbCtD
Cladribine—NR5A1—Vinblastine—lung cancer	0.0444	0.12	CbGbCtD
Cladribine—RRM2—Gemcitabine—lung cancer	0.0372	0.101	CbGbCtD
Cladribine—RRM1—Gemcitabine—lung cancer	0.0372	0.101	CbGbCtD
Cladribine—POLA1—Gemcitabine—lung cancer	0.0322	0.0872	CbGbCtD
Cladribine—SLC28A3—Gemcitabine—lung cancer	0.0322	0.0872	CbGbCtD
Cladribine—DCK—Gemcitabine—lung cancer	0.0198	0.0537	CbGbCtD
Cladribine—ABCG2—Topotecan—lung cancer	0.00771	0.0209	CbGbCtD
Cladribine—ABCG2—Gefitinib—lung cancer	0.00705	0.0191	CbGbCtD
Cladribine—ABCG2—Teniposide—lung cancer	0.00683	0.0185	CbGbCtD
Cladribine—SLC22A2—Vinblastine—lung cancer	0.00453	0.0123	CbGbCtD
Cladribine—ABCG2—Erlotinib—lung cancer	0.00417	0.0113	CbGbCtD
Cladribine—SLC22A2—Cisplatin—lung cancer	0.00416	0.0113	CbGbCtD
Cladribine—ABCG2—Paclitaxel—lung cancer	0.00381	0.0103	CbGbCtD
Cladribine—ABCG2—Irinotecan—lung cancer	0.00376	0.0102	CbGbCtD
Cladribine—ABCG2—Cisplatin—lung cancer	0.00307	0.00831	CbGbCtD
Cladribine—ABCG2—Etoposide—lung cancer	0.00301	0.00817	CbGbCtD
Cladribine—ABCG2—Docetaxel—lung cancer	0.00276	0.00747	CbGbCtD
Cladribine—ABCG2—Doxorubicin—lung cancer	0.00206	0.00557	CbGbCtD
Cladribine—ABCG2—Methotrexate—lung cancer	0.00199	0.0054	CbGbCtD
Cladribine—POLE3—mammary gland—lung cancer	0.00159	0.0476	CbGeAlD
Cladribine—POLE—mammary gland—lung cancer	0.00122	0.0363	CbGeAlD
Cladribine—PNP—respiratory system—lung cancer	0.00121	0.0361	CbGeAlD
Cladribine—RRM2B—respiratory system—lung cancer	0.00112	0.0335	CbGeAlD
Cladribine—POLE2—bone marrow—lung cancer	0.00112	0.0335	CbGeAlD
Cladribine—POLE3—respiratory system—lung cancer	0.00106	0.0317	CbGeAlD
Cladribine—POLA1—mammary gland—lung cancer	0.00105	0.0313	CbGeAlD
Cladribine—POLE2—lung—lung cancer	0.00102	0.0303	CbGeAlD
Cladribine—RRM2—mammary gland—lung cancer	0.001	0.0299	CbGeAlD
Cladribine—SLC28A3—respiratory system—lung cancer	0.000995	0.0297	CbGeAlD
Cladribine—RRM2B—bronchus—lung cancer	0.000925	0.0276	CbGeAlD
Cladribine—POLE3—bronchus—lung cancer	0.000875	0.0261	CbGeAlD
Cladribine—RRM1—mammary gland—lung cancer	0.000832	0.0248	CbGeAlD
Cladribine—RRM2B—trachea—lung cancer	0.000831	0.0248	CbGeAlD
Cladribine—POLE3—trachea—lung cancer	0.000785	0.0234	CbGeAlD
Cladribine—RRM2B—cardiac atrium—lung cancer	0.000781	0.0233	CbGeAlD
Cladribine—POLE3—cardiac atrium—lung cancer	0.000738	0.022	CbGeAlD
Cladribine—SLC28A3—trachea—lung cancer	0.000735	0.0219	CbGeAlD
Cladribine—PNP—bone marrow—lung cancer	0.00071	0.0212	CbGeAlD
Cladribine—POLE2—lymph node—lung cancer	0.000695	0.0207	CbGeAlD
Cladribine—RRM2—respiratory system—lung cancer	0.000668	0.0199	CbGeAlD
Cladribine—RRM2B—bone marrow—lung cancer	0.000659	0.0197	CbGeAlD
Cladribine—PNP—lung—lung cancer	0.000643	0.0192	CbGeAlD
Cladribine—POLE3—bone marrow—lung cancer	0.000623	0.0186	CbGeAlD
Cladribine—POLE—trachea—lung cancer	0.000599	0.0179	CbGeAlD
Cladribine—RRM2B—lung—lung cancer	0.000597	0.0178	CbGeAlD
Cladribine—SLC28A3—bone marrow—lung cancer	0.000583	0.0174	CbGeAlD
Cladribine—POLE3—lung—lung cancer	0.000564	0.0168	CbGeAlD
Cladribine—RRM1—respiratory system—lung cancer	0.000555	0.0165	CbGeAlD
Cladribine—RRM2—bronchus—lung cancer	0.00055	0.0164	CbGeAlD
Cladribine—SLC28A3—lung—lung cancer	0.000528	0.0158	CbGeAlD
Cladribine—Adenosine monophosphate—ADCY1—lung cancer	0.000502	0.206	CrCbGaD
Cladribine—POLE—bone marrow—lung cancer	0.000475	0.0142	CbGeAlD
Cladribine—RRM1—bronchus—lung cancer	0.000457	0.0136	CbGeAlD
Cladribine—Abacavir—UGT1A1—lung cancer	0.000454	0.186	CrCbGaD
Cladribine—POLE—lung—lung cancer	0.000431	0.0128	CbGeAlD
Cladribine—POLA1—bone marrow—lung cancer	0.00041	0.0122	CbGeAlD
Cladribine—RRM2B—lymph node—lung cancer	0.000408	0.0122	CbGeAlD
Cladribine—Clofarabine—RRM1—lung cancer	0.000398	0.163	CrCbGaD
Cladribine—RRM2—bone marrow—lung cancer	0.000391	0.0117	CbGeAlD
Cladribine—POLE3—lymph node—lung cancer	0.000386	0.0115	CbGeAlD
Cladribine—Fludarabine—RRM1—lung cancer	0.000385	0.158	CrCbGaD
Cladribine—RRM1—cardiac atrium—lung cancer	0.000385	0.0115	CbGeAlD
Cladribine—POLA1—lung—lung cancer	0.000371	0.0111	CbGeAlD
Cladribine—DCK—bronchus—lung cancer	0.000355	0.0106	CbGeAlD
Cladribine—RRM2—lung—lung cancer	0.000355	0.0106	CbGeAlD
Cladribine—RRM1—bone marrow—lung cancer	0.000325	0.0097	CbGeAlD
Cladribine—DCK—trachea—lung cancer	0.000318	0.0095	CbGeAlD
Cladribine—DCK—cardiac atrium—lung cancer	0.000299	0.00892	CbGeAlD
Cladribine—RRM1—lung—lung cancer	0.000295	0.00879	CbGeAlD
Cladribine—POLE—lymph node—lung cancer	0.000294	0.00879	CbGeAlD
Cladribine—Floxuridine—TYMS—lung cancer	0.00027	0.111	CrCbGaD
Cladribine—POLE2—Topotecan—Irinotecan—lung cancer	0.000256	0.12	CbGdCrCtD
Cladribine—POLA1—lymph node—lung cancer	0.000254	0.00757	CbGeAlD
Cladribine—DCK—bone marrow—lung cancer	0.000253	0.00753	CbGeAlD
Cladribine—RRM2—lymph node—lung cancer	0.000243	0.00723	CbGeAlD
Cladribine—DCK—lung—lung cancer	0.000229	0.00683	CbGeAlD
Cladribine—Trifluridine—TYMS—lung cancer	0.000214	0.0879	CrCbGaD
Cladribine—PNP—Erlotinib—Gefitinib—lung cancer	0.000207	0.0973	CbGdCrCtD
Cladribine—RRM1—lymph node—lung cancer	0.000201	0.00601	CbGeAlD
Cladribine—POLE2—Afatinib—Gefitinib—lung cancer	0.000176	0.0825	CbGdCrCtD
Cladribine—DCK—lymph node—lung cancer	0.000156	0.00467	CbGeAlD
Cladribine—ABCG2—bone marrow—lung cancer	0.000141	0.0042	CbGeAlD
Cladribine—RRM2—Afatinib—Gefitinib—lung cancer	0.000139	0.0655	CbGdCrCtD
Cladribine—PNP—Paclitaxel—Docetaxel—lung cancer	0.000138	0.065	CbGdCrCtD
Cladribine—RRM2—Gefitinib—Erlotinib—lung cancer	0.000137	0.0642	CbGdCrCtD
Cladribine—PNP—Afatinib—Gefitinib—lung cancer	0.000135	0.0636	CbGdCrCtD
Cladribine—PNP—Gefitinib—Erlotinib—lung cancer	0.000133	0.0624	CbGdCrCtD
Cladribine—ABCG2—lung—lung cancer	0.000128	0.00381	CbGeAlD
Cladribine—Adenosine monophosphate—SRC—lung cancer	0.000117	0.0477	CrCbGaD
Cladribine—POLE2—Teniposide—Etoposide—lung cancer	0.000115	0.0541	CbGdCrCtD
Cladribine—DCK—Topotecan—Irinotecan—lung cancer	0.000115	0.0541	CbGdCrCtD
Cladribine—POLA1—Vinblastine—Vinorelbine—lung cancer	0.000108	0.0509	CbGdCrCtD
Cladribine—Clofarabine—ABCG2—lung cancer	0.000102	0.0416	CrCbGaD
Cladribine—RRM2—Vinorelbine—Vinblastine—lung cancer	9.16e-05	0.043	CbGdCrCtD
Cladribine—ABCG2—lymph node—lung cancer	8.73e-05	0.0026	CbGeAlD
Cladribine—RRM1—Azacitidine—Gemcitabine—lung cancer	5.88e-05	0.0276	CbGdCrCtD
Cladribine—POLE2—Idarubicin—Doxorubicin—lung cancer	5.56e-05	0.0261	CbGdCrCtD
Cladribine—POLE2—Epirubicin—Doxorubicin—lung cancer	5.56e-05	0.0261	CbGdCrCtD
Cladribine—POLE2—Daunorubicin—Doxorubicin—lung cancer	5.56e-05	0.0261	CbGdCrCtD
Cladribine—POLE2—Azacitidine—Gemcitabine—lung cancer	4.65e-05	0.0218	CbGdCrCtD
Cladribine—PNP—Daunorubicin—Doxorubicin—lung cancer	4.29e-05	0.0202	CbGdCrCtD
Cladribine—RRM2—Azacitidine—Gemcitabine—lung cancer	3.69e-05	0.0173	CbGdCrCtD
Cladribine—Paraesthesia—Etoposide—lung cancer	2.58e-05	0.000279	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Paclitaxel—lung cancer	2.57e-05	0.000278	CcSEcCtD
Cladribine—Dyspnoea—Etoposide—lung cancer	2.56e-05	0.000277	CcSEcCtD
Cladribine—Somnolence—Etoposide—lung cancer	2.55e-05	0.000276	CcSEcCtD
Cladribine—Cough—Docetaxel—lung cancer	2.55e-05	0.000276	CcSEcCtD
Cladribine—Hepatobiliary disease—Methotrexate—lung cancer	2.55e-05	0.000276	CcSEcCtD
Cladribine—Insomnia—Paclitaxel—lung cancer	2.55e-05	0.000276	CcSEcCtD
Cladribine—Epistaxis—Methotrexate—lung cancer	2.55e-05	0.000275	CcSEcCtD
Cladribine—Hypersensitivity—Irinotecan—lung cancer	2.55e-05	0.000275	CcSEcCtD
Cladribine—Paraesthesia—Paclitaxel—lung cancer	2.53e-05	0.000274	CcSEcCtD
Cladribine—Dyspnoea—Paclitaxel—lung cancer	2.51e-05	0.000272	CcSEcCtD
Cladribine—DCK—Epirubicin—Doxorubicin—lung cancer	2.51e-05	0.0118	CbGdCrCtD
Cladribine—Somnolence—Paclitaxel—lung cancer	2.5e-05	0.000271	CcSEcCtD
Cladribine—Decreased appetite—Etoposide—lung cancer	2.5e-05	0.00027	CcSEcCtD
Cladribine—Arthralgia—Docetaxel—lung cancer	2.49e-05	0.000269	CcSEcCtD
Cladribine—Myalgia—Docetaxel—lung cancer	2.49e-05	0.000269	CcSEcCtD
Cladribine—Chest pain—Docetaxel—lung cancer	2.49e-05	0.000269	CcSEcCtD
Cladribine—Pancytopenia—Doxorubicin—lung cancer	2.49e-05	0.000269	CcSEcCtD
Cladribine—Nausea—Vinorelbine—lung cancer	2.49e-05	0.000269	CcSEcCtD
Cladribine—Gastrointestinal disorder—Etoposide—lung cancer	2.48e-05	0.000268	CcSEcCtD
Cladribine—Body temperature increased—Cisplatin—lung cancer	2.48e-05	0.000268	CcSEcCtD
Cladribine—Asthenia—Irinotecan—lung cancer	2.48e-05	0.000268	CcSEcCtD
Cladribine—Fatigue—Etoposide—lung cancer	2.48e-05	0.000268	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	2.47e-05	0.000268	CcSEcCtD
Cladribine—Pain—Etoposide—lung cancer	2.46e-05	0.000266	CcSEcCtD
Cladribine—Constipation—Etoposide—lung cancer	2.46e-05	0.000266	CcSEcCtD
Cladribine—Neutropenia—Doxorubicin—lung cancer	2.45e-05	0.000265	CcSEcCtD
Cladribine—Decreased appetite—Paclitaxel—lung cancer	2.45e-05	0.000265	CcSEcCtD
Cladribine—Upper respiratory tract infection—Doxorubicin—lung cancer	2.44e-05	0.000263	CcSEcCtD
Cladribine—Haemoglobin—Methotrexate—lung cancer	2.44e-05	0.000263	CcSEcCtD
Cladribine—Gastrointestinal disorder—Paclitaxel—lung cancer	2.43e-05	0.000263	CcSEcCtD
Cladribine—Fatigue—Paclitaxel—lung cancer	2.43e-05	0.000263	CcSEcCtD
Cladribine—Haemorrhage—Methotrexate—lung cancer	2.42e-05	0.000262	CcSEcCtD
Cladribine—Asthenia—Gemcitabine—lung cancer	2.41e-05	0.000261	CcSEcCtD
Cladribine—Pain—Paclitaxel—lung cancer	2.41e-05	0.000261	CcSEcCtD
Cladribine—Constipation—Paclitaxel—lung cancer	2.41e-05	0.000261	CcSEcCtD
Cladribine—Confusional state—Docetaxel—lung cancer	2.41e-05	0.00026	CcSEcCtD
Cladribine—Pharyngitis—Methotrexate—lung cancer	2.4e-05	0.00026	CcSEcCtD
Cladribine—Urinary tract disorder—Methotrexate—lung cancer	2.39e-05	0.000259	CcSEcCtD
Cladribine—Oedema—Docetaxel—lung cancer	2.39e-05	0.000258	CcSEcCtD
Cladribine—Pruritus—Gemcitabine—lung cancer	2.38e-05	0.000257	CcSEcCtD
Cladribine—Urethral disorder—Methotrexate—lung cancer	2.37e-05	0.000257	CcSEcCtD
Cladribine—Infection—Docetaxel—lung cancer	2.37e-05	0.000257	CcSEcCtD
Cladribine—Feeling abnormal—Etoposide—lung cancer	2.37e-05	0.000256	CcSEcCtD
Cladribine—Diarrhoea—Irinotecan—lung cancer	2.36e-05	0.000256	CcSEcCtD
Cladribine—Pneumonia—Doxorubicin—lung cancer	2.35e-05	0.000254	CcSEcCtD
Cladribine—Gastrointestinal pain—Etoposide—lung cancer	2.35e-05	0.000254	CcSEcCtD
Cladribine—Nervous system disorder—Docetaxel—lung cancer	2.34e-05	0.000253	CcSEcCtD
Cladribine—Thrombocytopenia—Docetaxel—lung cancer	2.34e-05	0.000253	CcSEcCtD
Cladribine—Infestation NOS—Doxorubicin—lung cancer	2.34e-05	0.000253	CcSEcCtD
Cladribine—Infestation—Doxorubicin—lung cancer	2.34e-05	0.000253	CcSEcCtD
Cladribine—Tachycardia—Docetaxel—lung cancer	2.33e-05	0.000252	CcSEcCtD
Cladribine—Feeling abnormal—Paclitaxel—lung cancer	2.32e-05	0.000251	CcSEcCtD
Cladribine—Skin disorder—Docetaxel—lung cancer	2.32e-05	0.000251	CcSEcCtD
Cladribine—Stevens-Johnson syndrome—Doxorubicin—lung cancer	2.32e-05	0.000251	CcSEcCtD
Cladribine—Hypersensitivity—Cisplatin—lung cancer	2.31e-05	0.00025	CcSEcCtD
Cladribine—Gastrointestinal pain—Paclitaxel—lung cancer	2.3e-05	0.000249	CcSEcCtD
Cladribine—Diarrhoea—Gemcitabine—lung cancer	2.3e-05	0.000249	CcSEcCtD
Cladribine—Renal failure—Doxorubicin—lung cancer	2.3e-05	0.000248	CcSEcCtD
Cladribine—Erythema multiforme—Methotrexate—lung cancer	2.29e-05	0.000248	CcSEcCtD
Cladribine—Dizziness—Irinotecan—lung cancer	2.28e-05	0.000247	CcSEcCtD
Cladribine—Urticaria—Etoposide—lung cancer	2.28e-05	0.000247	CcSEcCtD
Cladribine—Anorexia—Docetaxel—lung cancer	2.28e-05	0.000246	CcSEcCtD
Cladribine—Abdominal pain—Etoposide—lung cancer	2.27e-05	0.000246	CcSEcCtD
Cladribine—Body temperature increased—Etoposide—lung cancer	2.27e-05	0.000246	CcSEcCtD
Cladribine—Conjunctivitis—Doxorubicin—lung cancer	2.27e-05	0.000246	CcSEcCtD
Cladribine—Urinary tract infection—Doxorubicin—lung cancer	2.27e-05	0.000246	CcSEcCtD
Cladribine—Eye disorder—Methotrexate—lung cancer	2.26e-05	0.000245	CcSEcCtD
Cladribine—Asthenia—Cisplatin—lung cancer	2.25e-05	0.000243	CcSEcCtD
Cladribine—Cardiac disorder—Methotrexate—lung cancer	2.25e-05	0.000243	CcSEcCtD
Cladribine—Urticaria—Paclitaxel—lung cancer	2.24e-05	0.000242	CcSEcCtD
Cladribine—Hypotension—Docetaxel—lung cancer	2.23e-05	0.000241	CcSEcCtD
Cladribine—Abdominal pain—Paclitaxel—lung cancer	2.23e-05	0.000241	CcSEcCtD
Cladribine—Body temperature increased—Paclitaxel—lung cancer	2.23e-05	0.000241	CcSEcCtD
Cladribine—Hepatobiliary disease—Doxorubicin—lung cancer	2.21e-05	0.000239	CcSEcCtD
Cladribine—Epistaxis—Doxorubicin—lung cancer	2.2e-05	0.000238	CcSEcCtD
Cladribine—Angiopathy—Methotrexate—lung cancer	2.2e-05	0.000238	CcSEcCtD
Cladribine—Vomiting—Irinotecan—lung cancer	2.2e-05	0.000238	CcSEcCtD
Cladribine—Immune system disorder—Methotrexate—lung cancer	2.19e-05	0.000237	CcSEcCtD
Cladribine—Mediastinal disorder—Methotrexate—lung cancer	2.18e-05	0.000236	CcSEcCtD
Cladribine—Rash—Irinotecan—lung cancer	2.18e-05	0.000236	CcSEcCtD
Cladribine—Dermatitis—Irinotecan—lung cancer	2.18e-05	0.000235	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Docetaxel—lung cancer	2.18e-05	0.000235	CcSEcCtD
Cladribine—Chills—Methotrexate—lung cancer	2.17e-05	0.000235	CcSEcCtD
Cladribine—Headache—Irinotecan—lung cancer	2.16e-05	0.000234	CcSEcCtD
Cladribine—Insomnia—Docetaxel—lung cancer	2.16e-05	0.000234	CcSEcCtD
Cladribine—Diarrhoea—Cisplatin—lung cancer	2.15e-05	0.000232	CcSEcCtD
Cladribine—Paraesthesia—Docetaxel—lung cancer	2.14e-05	0.000232	CcSEcCtD
Cladribine—Alopecia—Methotrexate—lung cancer	2.14e-05	0.000231	CcSEcCtD
Cladribine—Vomiting—Gemcitabine—lung cancer	2.14e-05	0.000231	CcSEcCtD
Cladribine—Dyspnoea—Docetaxel—lung cancer	2.13e-05	0.00023	CcSEcCtD
Cladribine—Somnolence—Docetaxel—lung cancer	2.12e-05	0.00023	CcSEcCtD
Cladribine—Mental disorder—Methotrexate—lung cancer	2.12e-05	0.00023	CcSEcCtD
Cladribine—Rash—Gemcitabine—lung cancer	2.12e-05	0.000229	CcSEcCtD
Cladribine—Dermatitis—Gemcitabine—lung cancer	2.12e-05	0.000229	CcSEcCtD
Cladribine—Hypersensitivity—Etoposide—lung cancer	2.12e-05	0.000229	CcSEcCtD
Cladribine—Erythema—Methotrexate—lung cancer	2.11e-05	0.000228	CcSEcCtD
Cladribine—Malnutrition—Methotrexate—lung cancer	2.11e-05	0.000228	CcSEcCtD
Cladribine—Haemoglobin—Doxorubicin—lung cancer	2.11e-05	0.000228	CcSEcCtD
Cladribine—Headache—Gemcitabine—lung cancer	2.11e-05	0.000228	CcSEcCtD
Cladribine—Haemorrhage—Doxorubicin—lung cancer	2.1e-05	0.000227	CcSEcCtD
Cladribine—Pharyngitis—Doxorubicin—lung cancer	2.08e-05	0.000225	CcSEcCtD
Cladribine—Decreased appetite—Docetaxel—lung cancer	2.08e-05	0.000224	CcSEcCtD
Cladribine—Hypersensitivity—Paclitaxel—lung cancer	2.08e-05	0.000224	CcSEcCtD
Cladribine—Urinary tract disorder—Doxorubicin—lung cancer	2.07e-05	0.000224	CcSEcCtD
Cladribine—Oedema peripheral—Doxorubicin—lung cancer	2.07e-05	0.000223	CcSEcCtD
Cladribine—Gastrointestinal disorder—Docetaxel—lung cancer	2.06e-05	0.000223	CcSEcCtD
Cladribine—Asthenia—Etoposide—lung cancer	2.06e-05	0.000223	CcSEcCtD
Cladribine—Connective tissue disorder—Doxorubicin—lung cancer	2.06e-05	0.000223	CcSEcCtD
Cladribine—Fatigue—Docetaxel—lung cancer	2.06e-05	0.000223	CcSEcCtD
Cladribine—Urethral disorder—Doxorubicin—lung cancer	2.06e-05	0.000222	CcSEcCtD
Cladribine—Nausea—Irinotecan—lung cancer	2.05e-05	0.000222	CcSEcCtD
Cladribine—Pain—Docetaxel—lung cancer	2.04e-05	0.000221	CcSEcCtD
Cladribine—Constipation—Docetaxel—lung cancer	2.04e-05	0.000221	CcSEcCtD
Cladribine—Back pain—Methotrexate—lung cancer	2.04e-05	0.000221	CcSEcCtD
Cladribine—Pruritus—Etoposide—lung cancer	2.03e-05	0.00022	CcSEcCtD
Cladribine—Asthenia—Paclitaxel—lung cancer	2.02e-05	0.000219	CcSEcCtD
Cladribine—Nausea—Gemcitabine—lung cancer	2e-05	0.000216	CcSEcCtD
Cladribine—Vomiting—Cisplatin—lung cancer	1.99e-05	0.000216	CcSEcCtD
Cladribine—Pruritus—Paclitaxel—lung cancer	1.99e-05	0.000216	CcSEcCtD
Cladribine—Erythema multiforme—Doxorubicin—lung cancer	1.98e-05	0.000214	CcSEcCtD
Cladribine—Rash—Cisplatin—lung cancer	1.98e-05	0.000214	CcSEcCtD
Cladribine—Dermatitis—Cisplatin—lung cancer	1.98e-05	0.000214	CcSEcCtD
Cladribine—Feeling abnormal—Docetaxel—lung cancer	1.97e-05	0.000213	CcSEcCtD
Cladribine—Diarrhoea—Etoposide—lung cancer	1.97e-05	0.000213	CcSEcCtD
Cladribine—Eye disorder—Doxorubicin—lung cancer	1.96e-05	0.000212	CcSEcCtD
Cladribine—Ill-defined disorder—Methotrexate—lung cancer	1.96e-05	0.000212	CcSEcCtD
Cladribine—Gastrointestinal pain—Docetaxel—lung cancer	1.95e-05	0.000211	CcSEcCtD
Cladribine—Anaemia—Methotrexate—lung cancer	1.95e-05	0.000211	CcSEcCtD
Cladribine—Cardiac disorder—Doxorubicin—lung cancer	1.95e-05	0.000211	CcSEcCtD
Cladribine—Diarrhoea—Paclitaxel—lung cancer	1.93e-05	0.000208	CcSEcCtD
Cladribine—Angiopathy—Doxorubicin—lung cancer	1.9e-05	0.000206	CcSEcCtD
Cladribine—Malaise—Methotrexate—lung cancer	1.9e-05	0.000206	CcSEcCtD
Cladribine—Dizziness—Etoposide—lung cancer	1.9e-05	0.000205	CcSEcCtD
Cladribine—Immune system disorder—Doxorubicin—lung cancer	1.89e-05	0.000205	CcSEcCtD
Cladribine—Mediastinal disorder—Doxorubicin—lung cancer	1.89e-05	0.000204	CcSEcCtD
Cladribine—Abdominal pain—Docetaxel—lung cancer	1.89e-05	0.000204	CcSEcCtD
Cladribine—Body temperature increased—Docetaxel—lung cancer	1.89e-05	0.000204	CcSEcCtD
Cladribine—Chills—Doxorubicin—lung cancer	1.88e-05	0.000204	CcSEcCtD
Cladribine—Arrhythmia—Doxorubicin—lung cancer	1.87e-05	0.000203	CcSEcCtD
Cladribine—Dizziness—Paclitaxel—lung cancer	1.86e-05	0.000201	CcSEcCtD
Cladribine—Nausea—Cisplatin—lung cancer	1.86e-05	0.000201	CcSEcCtD
Cladribine—Alopecia—Doxorubicin—lung cancer	1.85e-05	0.0002	CcSEcCtD
Cladribine—Cough—Methotrexate—lung cancer	1.84e-05	0.000199	CcSEcCtD
Cladribine—Mental disorder—Doxorubicin—lung cancer	1.84e-05	0.000199	CcSEcCtD
Cladribine—Vomiting—Etoposide—lung cancer	1.83e-05	0.000198	CcSEcCtD
Cladribine—Erythema—Doxorubicin—lung cancer	1.83e-05	0.000197	CcSEcCtD
Cladribine—Malnutrition—Doxorubicin—lung cancer	1.83e-05	0.000197	CcSEcCtD
Cladribine—Rash—Etoposide—lung cancer	1.81e-05	0.000196	CcSEcCtD
Cladribine—Dermatitis—Etoposide—lung cancer	1.81e-05	0.000196	CcSEcCtD
Cladribine—Headache—Etoposide—lung cancer	1.8e-05	0.000195	CcSEcCtD
Cladribine—Flatulence—Doxorubicin—lung cancer	1.8e-05	0.000195	CcSEcCtD
Cladribine—Chest pain—Methotrexate—lung cancer	1.8e-05	0.000194	CcSEcCtD
Cladribine—Myalgia—Methotrexate—lung cancer	1.8e-05	0.000194	CcSEcCtD
Cladribine—Arthralgia—Methotrexate—lung cancer	1.8e-05	0.000194	CcSEcCtD
Cladribine—Vomiting—Paclitaxel—lung cancer	1.79e-05	0.000194	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	1.78e-05	0.000193	CcSEcCtD
Cladribine—Rash—Paclitaxel—lung cancer	1.78e-05	0.000192	CcSEcCtD
Cladribine—Dermatitis—Paclitaxel—lung cancer	1.77e-05	0.000192	CcSEcCtD
Cladribine—Discomfort—Methotrexate—lung cancer	1.77e-05	0.000192	CcSEcCtD
Cladribine—Back pain—Doxorubicin—lung cancer	1.77e-05	0.000191	CcSEcCtD
Cladribine—Headache—Paclitaxel—lung cancer	1.77e-05	0.000191	CcSEcCtD
Cladribine—Hypersensitivity—Docetaxel—lung cancer	1.76e-05	0.00019	CcSEcCtD
Cladribine—Confusional state—Methotrexate—lung cancer	1.74e-05	0.000188	CcSEcCtD
Cladribine—Asthenia—Docetaxel—lung cancer	1.71e-05	0.000185	CcSEcCtD
Cladribine—Infection—Methotrexate—lung cancer	1.71e-05	0.000185	CcSEcCtD
Cladribine—Nausea—Etoposide—lung cancer	1.71e-05	0.000185	CcSEcCtD
Cladribine—Ill-defined disorder—Doxorubicin—lung cancer	1.69e-05	0.000183	CcSEcCtD
Cladribine—Pruritus—Docetaxel—lung cancer	1.69e-05	0.000183	CcSEcCtD
Cladribine—Nervous system disorder—Methotrexate—lung cancer	1.69e-05	0.000183	CcSEcCtD
Cladribine—Anaemia—Doxorubicin—lung cancer	1.69e-05	0.000183	CcSEcCtD
Cladribine—Thrombocytopenia—Methotrexate—lung cancer	1.69e-05	0.000182	CcSEcCtD
Cladribine—Nausea—Paclitaxel—lung cancer	1.67e-05	0.000181	CcSEcCtD
Cladribine—Skin disorder—Methotrexate—lung cancer	1.67e-05	0.000181	CcSEcCtD
Cladribine—Hyperhidrosis—Methotrexate—lung cancer	1.66e-05	0.00018	CcSEcCtD
Cladribine—Malaise—Doxorubicin—lung cancer	1.65e-05	0.000178	CcSEcCtD
Cladribine—Anorexia—Methotrexate—lung cancer	1.64e-05	0.000177	CcSEcCtD
Cladribine—Diarrhoea—Docetaxel—lung cancer	1.63e-05	0.000177	CcSEcCtD
Cladribine—Hypotension—Methotrexate—lung cancer	1.61e-05	0.000174	CcSEcCtD
Cladribine—Cough—Doxorubicin—lung cancer	1.59e-05	0.000172	CcSEcCtD
Cladribine—Dizziness—Docetaxel—lung cancer	1.58e-05	0.000171	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Methotrexate—lung cancer	1.57e-05	0.00017	CcSEcCtD
Cladribine—Insomnia—Methotrexate—lung cancer	1.56e-05	0.000168	CcSEcCtD
Cladribine—Arthralgia—Doxorubicin—lung cancer	1.55e-05	0.000168	CcSEcCtD
Cladribine—Myalgia—Doxorubicin—lung cancer	1.55e-05	0.000168	CcSEcCtD
Cladribine—Chest pain—Doxorubicin—lung cancer	1.55e-05	0.000168	CcSEcCtD
Cladribine—Anxiety—Doxorubicin—lung cancer	1.55e-05	0.000168	CcSEcCtD
Cladribine—Paraesthesia—Methotrexate—lung cancer	1.55e-05	0.000167	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	1.54e-05	0.000167	CcSEcCtD
Cladribine—Discomfort—Doxorubicin—lung cancer	1.54e-05	0.000166	CcSEcCtD
Cladribine—Dyspnoea—Methotrexate—lung cancer	1.53e-05	0.000166	CcSEcCtD
Cladribine—Somnolence—Methotrexate—lung cancer	1.53e-05	0.000165	CcSEcCtD
Cladribine—Vomiting—Docetaxel—lung cancer	1.52e-05	0.000164	CcSEcCtD
Cladribine—Rash—Docetaxel—lung cancer	1.51e-05	0.000163	CcSEcCtD
Cladribine—Dermatitis—Docetaxel—lung cancer	1.5e-05	0.000163	CcSEcCtD
Cladribine—Confusional state—Doxorubicin—lung cancer	1.5e-05	0.000163	CcSEcCtD
Cladribine—Decreased appetite—Methotrexate—lung cancer	1.5e-05	0.000162	CcSEcCtD
Cladribine—Headache—Docetaxel—lung cancer	1.5e-05	0.000162	CcSEcCtD
Cladribine—Oedema—Doxorubicin—lung cancer	1.49e-05	0.000161	CcSEcCtD
Cladribine—Gastrointestinal disorder—Methotrexate—lung cancer	1.49e-05	0.000161	CcSEcCtD
Cladribine—Fatigue—Methotrexate—lung cancer	1.48e-05	0.00016	CcSEcCtD
Cladribine—Infection—Doxorubicin—lung cancer	1.48e-05	0.00016	CcSEcCtD
Cladribine—Pain—Methotrexate—lung cancer	1.47e-05	0.000159	CcSEcCtD
Cladribine—Nervous system disorder—Doxorubicin—lung cancer	1.46e-05	0.000158	CcSEcCtD
Cladribine—Thrombocytopenia—Doxorubicin—lung cancer	1.46e-05	0.000158	CcSEcCtD
Cladribine—Tachycardia—Doxorubicin—lung cancer	1.45e-05	0.000157	CcSEcCtD
Cladribine—Skin disorder—Doxorubicin—lung cancer	1.45e-05	0.000157	CcSEcCtD
Cladribine—Hyperhidrosis—Doxorubicin—lung cancer	1.44e-05	0.000156	CcSEcCtD
Cladribine—Anorexia—Doxorubicin—lung cancer	1.42e-05	0.000154	CcSEcCtD
Cladribine—Nausea—Docetaxel—lung cancer	1.42e-05	0.000153	CcSEcCtD
Cladribine—Feeling abnormal—Methotrexate—lung cancer	1.42e-05	0.000153	CcSEcCtD
Cladribine—Gastrointestinal pain—Methotrexate—lung cancer	1.41e-05	0.000152	CcSEcCtD
Cladribine—Hypotension—Doxorubicin—lung cancer	1.39e-05	0.000151	CcSEcCtD
Cladribine—Urticaria—Methotrexate—lung cancer	1.37e-05	0.000148	CcSEcCtD
Cladribine—Abdominal pain—Methotrexate—lung cancer	1.36e-05	0.000147	CcSEcCtD
Cladribine—Body temperature increased—Methotrexate—lung cancer	1.36e-05	0.000147	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Doxorubicin—lung cancer	1.36e-05	0.000147	CcSEcCtD
Cladribine—Insomnia—Doxorubicin—lung cancer	1.35e-05	0.000146	CcSEcCtD
Cladribine—Paraesthesia—Doxorubicin—lung cancer	1.34e-05	0.000145	CcSEcCtD
Cladribine—Dyspnoea—Doxorubicin—lung cancer	1.33e-05	0.000144	CcSEcCtD
Cladribine—Somnolence—Doxorubicin—lung cancer	1.32e-05	0.000143	CcSEcCtD
Cladribine—Decreased appetite—Doxorubicin—lung cancer	1.3e-05	0.00014	CcSEcCtD
Cladribine—Gastrointestinal disorder—Doxorubicin—lung cancer	1.29e-05	0.000139	CcSEcCtD
Cladribine—Fatigue—Doxorubicin—lung cancer	1.28e-05	0.000139	CcSEcCtD
Cladribine—Pain—Doxorubicin—lung cancer	1.27e-05	0.000138	CcSEcCtD
Cladribine—Constipation—Doxorubicin—lung cancer	1.27e-05	0.000138	CcSEcCtD
Cladribine—Hypersensitivity—Methotrexate—lung cancer	1.27e-05	0.000137	CcSEcCtD
Cladribine—Asthenia—Methotrexate—lung cancer	1.23e-05	0.000134	CcSEcCtD
Cladribine—Feeling abnormal—Doxorubicin—lung cancer	1.23e-05	0.000133	CcSEcCtD
Cladribine—Gastrointestinal pain—Doxorubicin—lung cancer	1.22e-05	0.000132	CcSEcCtD
Cladribine—Pruritus—Methotrexate—lung cancer	1.22e-05	0.000132	CcSEcCtD
Cladribine—Urticaria—Doxorubicin—lung cancer	1.18e-05	0.000128	CcSEcCtD
Cladribine—Abdominal pain—Doxorubicin—lung cancer	1.18e-05	0.000127	CcSEcCtD
Cladribine—Body temperature increased—Doxorubicin—lung cancer	1.18e-05	0.000127	CcSEcCtD
Cladribine—Diarrhoea—Methotrexate—lung cancer	1.18e-05	0.000127	CcSEcCtD
Cladribine—Dizziness—Methotrexate—lung cancer	1.14e-05	0.000123	CcSEcCtD
Cladribine—Hypersensitivity—Doxorubicin—lung cancer	1.1e-05	0.000119	CcSEcCtD
Cladribine—Vomiting—Methotrexate—lung cancer	1.09e-05	0.000118	CcSEcCtD
Cladribine—Rash—Methotrexate—lung cancer	1.09e-05	0.000117	CcSEcCtD
Cladribine—Dermatitis—Methotrexate—lung cancer	1.08e-05	0.000117	CcSEcCtD
Cladribine—Headache—Methotrexate—lung cancer	1.08e-05	0.000117	CcSEcCtD
Cladribine—Asthenia—Doxorubicin—lung cancer	1.07e-05	0.000116	CcSEcCtD
Cladribine—Pruritus—Doxorubicin—lung cancer	1.05e-05	0.000114	CcSEcCtD
Cladribine—Nausea—Methotrexate—lung cancer	1.02e-05	0.000111	CcSEcCtD
Cladribine—Diarrhoea—Doxorubicin—lung cancer	1.02e-05	0.00011	CcSEcCtD
Cladribine—Dizziness—Doxorubicin—lung cancer	9.86e-06	0.000107	CcSEcCtD
Cladribine—Vomiting—Doxorubicin—lung cancer	9.48e-06	0.000102	CcSEcCtD
Cladribine—Rash—Doxorubicin—lung cancer	9.4e-06	0.000102	CcSEcCtD
Cladribine—Dermatitis—Doxorubicin—lung cancer	9.39e-06	0.000102	CcSEcCtD
Cladribine—Headache—Doxorubicin—lung cancer	9.34e-06	0.000101	CcSEcCtD
Cladribine—Nausea—Doxorubicin—lung cancer	8.85e-06	9.57e-05	CcSEcCtD
Cladribine—SLC22A1—Transmission across Chemical Synapses—MDM2—lung cancer	7.07e-06	0.00012	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	7.05e-06	0.00012	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—RAF1—lung cancer	7.05e-06	0.00012	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTEN—lung cancer	7.03e-06	0.00012	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PGAM1—lung cancer	7.01e-06	0.000119	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ABCB1—lung cancer	6.97e-06	0.000119	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—BRAF—lung cancer	6.94e-06	0.000118	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—MYC—lung cancer	6.91e-06	0.000117	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CNDP2—lung cancer	6.89e-06	0.000117	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTM2—lung cancer	6.89e-06	0.000117	CbGpPWpGaD
Cladribine—DCK—Metabolism—GSTP1—lung cancer	6.88e-06	0.000117	CbGpPWpGaD
Cladribine—RRM2—Metabolism—TYMS—lung cancer	6.84e-06	0.000116	CbGpPWpGaD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—ALB—lung cancer	6.78e-06	0.000115	CbGpPWpGaD
Cladribine—POLA1—Mitotic M-M/G1 phases—MAPK3—lung cancer	6.76e-06	0.000115	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GSTM1—lung cancer	6.76e-06	0.000115	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP2A7—lung cancer	6.76e-06	0.000115	CbGpPWpGaD
Cladribine—PNP—Metabolism—EP300—lung cancer	6.7e-06	0.000114	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—MTMR3—lung cancer	6.7e-06	0.000114	CbGpPWpGaD
Cladribine—DCK—Metabolism—CAT—lung cancer	6.69e-06	0.000114	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP2A7—lung cancer	6.69e-06	0.000114	CbGpPWpGaD
Cladribine—RRM1—Metabolism—APOA1—lung cancer	6.68e-06	0.000114	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MAPK3—lung cancer	6.61e-06	0.000113	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SDC4—lung cancer	6.61e-06	0.000112	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SDC4—lung cancer	6.54e-06	0.000111	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PGAM1—lung cancer	6.53e-06	0.000111	CbGpPWpGaD
Cladribine—DCK—Metabolism—ABCB1—lung cancer	6.51e-06	0.000111	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN2A—lung cancer	6.49e-06	0.00011	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—BRAF—lung cancer	6.47e-06	0.00011	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—MYC—lung cancer	6.43e-06	0.000109	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CYP1A1—lung cancer	6.41e-06	0.000109	CbGpPWpGaD
Cladribine—DCK—Metabolism—TYMS—lung cancer	6.39e-06	0.000109	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ERCC2—lung cancer	6.36e-06	0.000108	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MAPK3—lung cancer	6.35e-06	0.000108	CbGpPWpGaD
Cladribine—DCK—Metabolism—GSTM1—lung cancer	6.32e-06	0.000108	CbGpPWpGaD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—ALB—lung cancer	6.32e-06	0.000107	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MDM2—lung cancer	6.3e-06	0.000107	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP2A7—lung cancer	6.23e-06	0.000106	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—MYC—lung cancer	6.17e-06	0.000105	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CCND1—lung cancer	6.13e-06	0.000104	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SDC4—lung cancer	6.1e-06	0.000104	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CG—lung cancer	6.1e-06	0.000104	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTA3—lung cancer	6.02e-06	0.000102	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—RRM1—lung cancer	6.02e-06	0.000102	CbGpPWpGaD
Cladribine—DCK—Metabolism—CYP1A1—lung cancer	5.99e-06	0.000102	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—RRM1—lung cancer	5.96e-06	0.000101	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTA3—lung cancer	5.96e-06	0.000101	CbGpPWpGaD
Cladribine—DCK—Metabolism—ERCC2—lung cancer	5.94e-06	0.000101	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—CDKN1A—lung cancer	5.93e-06	0.000101	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—MDM2—lung cancer	5.81e-06	9.89e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—POMC—lung cancer	5.81e-06	9.88e-05	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—RAF1—lung cancer	5.79e-06	9.85e-05	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—AVP—lung cancer	5.74e-06	9.77e-05	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MAPK3—lung cancer	5.74e-06	9.77e-05	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PIK3CA—lung cancer	5.72e-06	9.73e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—AVP—lung cancer	5.68e-06	9.67e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—B4GALT5—lung cancer	5.66e-06	9.63e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CREBBP—lung cancer	5.65e-06	9.62e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—EP300—lung cancer	5.65e-06	9.61e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—B4GALT5—lung cancer	5.6e-06	9.53e-05	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—MYC—lung cancer	5.58e-06	9.5e-05	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—ABCB1—lung cancer	5.56e-06	9.46e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTA3—lung cancer	5.56e-06	9.45e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—RRM1—lung cancer	5.56e-06	9.45e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTA4—lung cancer	5.51e-06	9.37e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—ABCB1—lung cancer	5.51e-06	9.37e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—APOA1—lung cancer	5.5e-06	9.36e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CCND1—lung cancer	5.48e-06	9.33e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTA4—lung cancer	5.45e-06	9.27e-05	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—MDM2—lung cancer	5.42e-06	9.22e-05	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—RAF1—lung cancer	5.4e-06	9.19e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTA2—lung cancer	5.37e-06	9.13e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CD—lung cancer	5.36e-06	9.12e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTA2—lung cancer	5.31e-06	9.04e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—CDKN1A—lung cancer	5.31e-06	9.03e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—AVP—lung cancer	5.3e-06	9.01e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—ALB—lung cancer	5.29e-06	9e-05	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—lung cancer	5.28e-06	8.99e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—B4GALT5—lung cancer	5.22e-06	8.89e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTA1—lung cancer	5.18e-06	8.81e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—APOA1—lung cancer	5.14e-06	8.75e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—ABCB1—lung cancer	5.13e-06	8.73e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTA1—lung cancer	5.13e-06	8.72e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ABCC3—lung cancer	5.12e-06	8.71e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTA4—lung cancer	5.08e-06	8.64e-05	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—lung cancer	5.07e-06	8.63e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ABCC3—lung cancer	5.07e-06	8.62e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MAPK3—lung cancer	5.06e-06	8.61e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—EP300—lung cancer	5.05e-06	8.59e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CG—lung cancer	5.02e-06	8.54e-05	CbGpPWpGaD
Cladribine—PNP—Metabolism—PIK3CA—lung cancer	4.96e-06	8.44e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—AKR1C1—lung cancer	4.96e-06	8.44e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTA2—lung cancer	4.95e-06	8.42e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—MYC—lung cancer	4.92e-06	8.37e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—AKR1C1—lung cancer	4.91e-06	8.35e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—UGT1A1—lung cancer	4.82e-06	8.19e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—POMC—lung cancer	4.78e-06	8.13e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTA1—lung cancer	4.78e-06	8.13e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—UGT1A1—lung cancer	4.77e-06	8.11e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ABCC3—lung cancer	4.72e-06	8.04e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CG—lung cancer	4.69e-06	7.98e-05	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—AKT1—lung cancer	4.67e-06	7.95e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CB—lung cancer	4.67e-06	7.95e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CREBBP—lung cancer	4.66e-06	7.92e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GNG11—lung cancer	4.64e-06	7.9e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTGS2—lung cancer	4.63e-06	7.88e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GNG11—lung cancer	4.6e-06	7.82e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—AKR1C1—lung cancer	4.58e-06	7.78e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MAPK3—lung cancer	4.52e-06	7.7e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—POMC—lung cancer	4.47e-06	7.6e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—UGT1A1—lung cancer	4.44e-06	7.56e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ALDOA—lung cancer	4.42e-06	7.52e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CD—lung cancer	4.42e-06	7.51e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—MYC—lung cancer	4.4e-06	7.48e-05	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—APOA1—lung cancer	4.39e-06	7.47e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ALDOA—lung cancer	4.38e-06	7.44e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—ALB—lung cancer	4.36e-06	7.41e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—CREBBP—lung cancer	4.35e-06	7.4e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—APOA1—lung cancer	4.35e-06	7.39e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NCOA3—lung cancer	4.29e-06	7.3e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GNG11—lung cancer	4.28e-06	7.29e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NCOA3—lung cancer	4.25e-06	7.23e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ADCY1—lung cancer	4.17e-06	7.1e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—HRAS—lung cancer	4.16e-06	7.08e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ADCY1—lung cancer	4.13e-06	7.03e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ABCG2—lung cancer	4.13e-06	7.03e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CD—lung cancer	4.13e-06	7.02e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ENO2—lung cancer	4.09e-06	6.96e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—HPGDS—lung cancer	4.09e-06	6.96e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ALDOA—lung cancer	4.08e-06	6.94e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—ALB—lung cancer	4.07e-06	6.93e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PPP2R1B—lung cancer	4.07e-06	6.92e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—HPGDS—lung cancer	4.05e-06	6.89e-05	CbGpPWpGaD
Cladribine—PNP—Metabolism—AKT1—lung cancer	4.05e-06	6.89e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ENO2—lung cancer	4.05e-06	6.89e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—APOA1—lung cancer	4.05e-06	6.89e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTEN—lung cancer	4.04e-06	6.87e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PPP2R1B—lung cancer	4.03e-06	6.85e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTT1—lung cancer	3.97e-06	6.76e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NCOA3—lung cancer	3.96e-06	6.73e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTT1—lung cancer	3.93e-06	6.69e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GCLC—lung cancer	3.93e-06	6.68e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP2A6—lung cancer	3.93e-06	6.68e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GCLC—lung cancer	3.88e-06	6.61e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP2A6—lung cancer	3.88e-06	6.61e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—HRAS—lung cancer	3.88e-06	6.6e-05	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—AKT1—lung cancer	3.87e-06	6.59e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—EP300—lung cancer	3.85e-06	6.55e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ABCG2—lung cancer	3.85e-06	6.55e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ADCY1—lung cancer	3.85e-06	6.55e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CB—lung cancer	3.85e-06	6.55e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTGS2—lung cancer	3.81e-06	6.49e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ENO2—lung cancer	3.78e-06	6.42e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—HPGDS—lung cancer	3.78e-06	6.42e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PPP2R1B—lung cancer	3.75e-06	6.38e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ENO1—lung cancer	3.72e-06	6.33e-05	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—CREBBP—lung cancer	3.72e-06	6.32e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ENO1—lung cancer	3.68e-06	6.26e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—CREBBP—lung cancer	3.68e-06	6.26e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTT1—lung cancer	3.66e-06	6.23e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GCLC—lung cancer	3.62e-06	6.16e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP2A6—lung cancer	3.62e-06	6.16e-05	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—lung cancer	3.61e-06	6.15e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CB—lung cancer	3.6e-06	6.12e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTGS2—lung cancer	3.56e-06	6.06e-05	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—ALB—lung cancer	3.48e-06	5.92e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—ALB—lung cancer	3.44e-06	5.86e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ENO1—lung cancer	3.43e-06	5.84e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—CREBBP—lung cancer	3.43e-06	5.83e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP2E1—lung cancer	3.34e-06	5.68e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTEN—lung cancer	3.33e-06	5.66e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP2E1—lung cancer	3.3e-06	5.62e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—NQO1—lung cancer	3.3e-06	5.61e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—NQO1—lung cancer	3.27e-06	5.56e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—ALB—lung cancer	3.21e-06	5.46e-05	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—HRAS—lung cancer	3.19e-06	5.43e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—EP300—lung cancer	3.17e-06	5.39e-05	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—RAF1—lung cancer	3.15e-06	5.35e-05	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—RAF1—lung cancer	3.11e-06	5.3e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTEN—lung cancer	3.11e-06	5.29e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP2E1—lung cancer	3.08e-06	5.24e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—NQO1—lung cancer	3.04e-06	5.18e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—STK11—lung cancer	2.97e-06	5.06e-05	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—HRAS—lung cancer	2.97e-06	5.06e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—EP300—lung cancer	2.96e-06	5.04e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—STK11—lung cancer	2.94e-06	5.01e-05	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—RAF1—lung cancer	2.9e-06	4.94e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PIK3CA—lung cancer	2.85e-06	4.85e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTP1—lung cancer	2.75e-06	4.68e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—STK11—lung cancer	2.74e-06	4.67e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTP1—lung cancer	2.72e-06	4.63e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CAT—lung cancer	2.68e-06	4.56e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CAT—lung cancer	2.65e-06	4.51e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ABCB1—lung cancer	2.61e-06	4.43e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ABCB1—lung cancer	2.58e-06	4.39e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—TYMS—lung cancer	2.56e-06	4.35e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTP1—lung cancer	2.54e-06	4.32e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—TYMS—lung cancer	2.53e-06	4.31e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTM1—lung cancer	2.53e-06	4.3e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTM1—lung cancer	2.5e-06	4.26e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CAT—lung cancer	2.47e-06	4.2e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ABCB1—lung cancer	2.4e-06	4.09e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CYP1A1—lung cancer	2.4e-06	4.08e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ERCC2—lung cancer	2.38e-06	4.05e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CYP1A1—lung cancer	2.37e-06	4.04e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—TYMS—lung cancer	2.36e-06	4.02e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ERCC2—lung cancer	2.35e-06	4e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PIK3CA—lung cancer	2.35e-06	3.99e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTM1—lung cancer	2.33e-06	3.97e-05	CbGpPWpGaD
Cladribine—RRM1—Metabolism—AKT1—lung cancer	2.33e-06	3.96e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CYP1A1—lung cancer	2.21e-06	3.76e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ERCC2—lung cancer	2.19e-06	3.73e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—PIK3CA—lung cancer	2.19e-06	3.73e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—APOA1—lung cancer	2.06e-06	3.5e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—APOA1—lung cancer	2.04e-06	3.46e-05	CbGpPWpGaD
Cladribine—RRM2—Metabolism—AKT1—lung cancer	1.92e-06	3.26e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—APOA1—lung cancer	1.9e-06	3.23e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CG—lung cancer	1.88e-06	3.2e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CG—lung cancer	1.86e-06	3.16e-05	CbGpPWpGaD
Cladribine—DCK—Metabolism—AKT1—lung cancer	1.79e-06	3.05e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—POMC—lung cancer	1.79e-06	3.04e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—POMC—lung cancer	1.77e-06	3.01e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CREBBP—lung cancer	1.74e-06	2.96e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CG—lung cancer	1.73e-06	2.95e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CREBBP—lung cancer	1.72e-06	2.93e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CD—lung cancer	1.65e-06	2.81e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—POMC—lung cancer	1.65e-06	2.81e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CD—lung cancer	1.63e-06	2.78e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—ALB—lung cancer	1.63e-06	2.77e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—ALB—lung cancer	1.61e-06	2.74e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CREBBP—lung cancer	1.61e-06	2.73e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CD—lung cancer	1.52e-06	2.59e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—ALB—lung cancer	1.5e-06	2.56e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CB—lung cancer	1.44e-06	2.45e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTGS2—lung cancer	1.43e-06	2.43e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CB—lung cancer	1.42e-06	2.42e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTGS2—lung cancer	1.41e-06	2.4e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CB—lung cancer	1.33e-06	2.26e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTGS2—lung cancer	1.32e-06	2.24e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTEN—lung cancer	1.24e-06	2.12e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTEN—lung cancer	1.23e-06	2.09e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—EP300—lung cancer	1.19e-06	2.02e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—EP300—lung cancer	1.17e-06	2e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTEN—lung cancer	1.15e-06	1.95e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—EP300—lung cancer	1.09e-06	1.86e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PIK3CA—lung cancer	8.77e-07	1.49e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PIK3CA—lung cancer	8.68e-07	1.48e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PIK3CA—lung cancer	8.09e-07	1.38e-05	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—AKT1—lung cancer	7.17e-07	1.22e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—AKT1—lung cancer	7.09e-07	1.21e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—AKT1—lung cancer	6.61e-07	1.12e-05	CbGpPWpGaD
